We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Rapid Diagnostic Test to Tackle Fatal Sleeping Sickness

By LabMedica International staff writers
Posted on 27 Jan 2016
Print article
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated  with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Image: The bite of an infected female tsetse fly taking a bloodmeal can transmit Trypanosoma brucei gambiense, cause of Human African Trypanosomiasis (HAT), also called African sleeping sickness, usually fatal if untreated with patients falling into a coma before death (Photo David Bygott/Flickr, courtesy of Biotechnology and Biological Sciences Research Council (UK)).
Using an innovative approach, scientists have developed a simple serodiagnostic method, similar to a dipstick pregnancy test, to fight human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense. The new test requires only a pin-prick blood sample and will remove the need to take complex equipment into remote areas.

Although millions are at risk of contracting HAT, some at-risk areas remain uncovered by surveillance and control efforts. Existing tests for T. b. gambiense rely on samples extracted directly from this dangerous parasite. A research team, led by Dr Barrie Rooney and Prof. Mark Smales of the University of Kent (Kent, UK), has designed a safer, easier, faster (about half the time of traditional methods), and less costly method for preparing samples. Also, fewer people will be needed to administer the test.

This next-generation test is based on genetic engineering to express selected T.b. gambiense recombinant antigens in a safe, easy-to-grow strain of the non-human parasite Leishmania tarentolae.

The work is part of the Biotechnology and Biological Sciences Research Council (BBSRC)’s Flexible Interchange Program (FLIP) in a project with Medecins Sans Frontieres (MSF; Geneva, Switzerland). Dr Rooney said: “I have been involved with MSF mobile HAT screening teams in central African countries for over 10 years. Traditional testing involves a large team in remote areas doing time-consuming microscopic work, and painful lumbar punctures. For this you need electricity and refrigeration. By combining the latest genome databases and old fashioned fermentation techniques we have come up with a fast, simple way of making robust and reliable tests. The new tests are designed to be heat-stable and user-friendly, like a dipstick pregnancy test. It will be a major improvement for screening and treatment of this deadly disease and speed us on the way to ‘the elimination of sleeping sickness as a public health hazard’ which is a World Health Organization target.”

Prof. Melanie Welham, executive director, BBSRC, Science, said, “This is a brilliant example of exactly what the FLIP scheme is all about. FLIP funding allowed Dr Rooney to work with the University of Kent and MSF to design and develop this test in just 14 months. The promise and potential impact of this new diagnostic is obvious and I wish Dr Rooney success in the forthcoming work in the Democratic Republic of the Congo (DRC). FLIP brings scientists into different environments where they can learn new skills and exploit their existing expertise in new collaborations, enhancing the impact of bioscience research.”

In July, Dr Rooney traveled to DRC to identify areas where field trials of the new test could be carried out, alongside an MSF HAT mobile team. The method also has potential to be developed for diagnosis of other tropical diseases, such as Chagas disease (T. cruzi) and visceral leishmaniasis.

The study, by Rooney B et al., was published December, 2015, in the journal PLOS Neglected Tropical Diseases.

Related Links:

University of Kent
Biotechnology and Biological Sciences Research Council (BBSRC) 
Medecins Sans Frontieres


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.